ClinicalTrials.gg

Program

AMO959

A development code. Also written as “BY101298 Capsules”.

In Novartis's pipeline, DNA PK inhibitor. Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Jun 12, 20242 company-led studies, 2 open or runningNext primary completion: Jul 10, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Baiyu Pharmaceutical11 open or runningphase 1since Jun 12, 2024Jun 12, 2024none ahead
Novartis11 open or runningphase 2since Nov 7, 2025Nov 7, 2025Jul 10, 2028phase 2 · NCT07226986
  • Named in Novartis’s own pipeline as AMO959, phase 1, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2024First study: phase 1 study in Solid Tumor, AdultNew to Chengdu Baiyu PharmaceuticalChengdu Baiyu Pharmaceutical · NCT06462716 · 36 enrolled · China
  2. Nov 7, 2025Novartis's first study: phase 2 study in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyNew to NovartisNovartis · NCT07226986 · 123 planned · United States, Australia, France and more

Ahead

  1. Jul 10, 2028Primary completion: phase 2 study in PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based ChemotherapyNovartis · NCT07226986

TargetBeta

“DNA PK inhibitor”the company's pipeline, read by Claude · source

Other programs on PRKDC

ProgramCompanyFurthest phaseStudies
bosmolisibruleBoryung Pharmaceuticalphase 22

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07226986PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy · United States, Australia, France and more2RecruitingNovartisJul 10, 2028123
NCT06462716Solid Tumor, Adult · China1Active, not recruitingChengdu Baiyu PharmaceuticalDec 31, 202436

How it is read

Names in the registry

  • “AMO959”, 1 entry
  • “BY101298 Capsules”, 1 entry

Codes read as this program: AMO959, BY101298.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.